Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Gastroenterology | Family Medicine
Clinical Trials: Crohn's Disease
A listing of clinical trials currently looking for volunteers to enroll in Crohn's Disease studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Birmingham : University of Alabama at Birmingham
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Birmingham : Apex Clinical Trials
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Birmingham : University of Alabama at Birmingham
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Birmingham : Apex Clinical Trials
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Mobile :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Arizona
Little Rock : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Little Rock : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Phoenix :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Scottsdale : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Scottsdale : Pfizer Investigational Site
B0151003 Open-Label Extension Study
View More »
Tucson : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Tucson : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Tucson : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Tucson : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Tucson : Visions Clinical Research - Tucson
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Tuscon : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Arkansas
Little Rock : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Little Rock : Preferred Research Partners
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Little Rock : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
California
Los Angeles : Gastrointestinal Bioscience
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Los Angeles : Gastrointestinal Bioscience
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Montebello : Paramount Medical Specialty
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Montebello : Paramount Medical Specialty
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Sacramento : Capital Gastroenterology Consultants Medical Group
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Sacramento : Capital Gastroenterology Consultants Medical Group
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
San Diego : Clinical Applications Laboratories Inc.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
San Diego : Desta Digestive Disease Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
San Diego : Desta Digestive Disease Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
San Diego : Clinical Applications Laboratories Inc.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Anaheim : Advanced Clinical Research Institute - Phase 1, LLC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Anaheim : AGMG Endoscopy Center
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Anaheim : Anaheim Clinical Trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Francisco :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Glendale : Research Site
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
La Jolla : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
La Jolla : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
La Jolla : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
La Jolla : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
La Jolla : University of California, San Diego
OTIS Autoimmune Diseases in Pregnancy Project
La Jolla : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
La Mesa : Rokay Kamyar, MD Inc
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
La Mirada : Medvin Clinical Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Lakewood : Lakewood Primary Care Medical Group, Inc
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Long Beach : Alliance Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Long Beach : Collaborative Neuroscience Network, Inc.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Los Angeles : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Los Angeles : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Los Angeles : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Los Angeles :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Oakland :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Orange : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Orange : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Redlands : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
San Carlos : Digestive Care Associates, LLC
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
San Carlos : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
San Diego : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
San Diego : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
San Diego : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
San Diego : Precision Research Institute, LLC
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
San Diego : San Diego Clinical Trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
San Diego : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
San Diego :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
San Francisco : University of California at San Francisco
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
San Francisco : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
San Francisco : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
San Francisco : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
San Francisco : University of California, San Francisco
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
San Francisco : University of California, San Francisco
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
San Francisco : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
San Francisco : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
SanDiego : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Santa Monica : Southern California Medical Gastroenterology Group
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Whittier : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Colorado
Aurora : University of Colorado Health Sciences Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Aurora : University of Colorado Health Sciences Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Golden : Rocky Mountain Clinical Research, LLC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Golden : Rocky Mountain Clinical Research, LLC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Lafayette : Gastroenterology of the Rockies
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Lafayette : Gastroenterology of the Rockies
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Littleton : Arapahoe Gastroenterology Associates P.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Littleton : Arapahoe Gastroenterology Associates P.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Lone Tree : South Denver Gastroenterology
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Lone Tree : South Denver Gastroenterology
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Pueblo : Lynn Institute of Pueblo
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Pueblo : Lynn Institute of Pueblo
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Denver : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Denver : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Denver :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Lafayette : Gastroenterology of the Rockies
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Lafayette : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Lakewood : Rocky Mountain Gastroenterology Associates
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Lakewood : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Lakewood : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Lakewood : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Lakewood : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Littleton : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Littleton : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Littleton : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Littleton : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Lone Tree : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lone Tree : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Thornton : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Thornton : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Connecticut
Bristol : Connecticut Gastroenterology Institute
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Bristol : Connecticut Gastroenterology Institute
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Hamden : Gastroenterology Center of Connecticut, P.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Hamden : Gastroenterology Center of Connecticut, P.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Bridgeport : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Hamden : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Hamden : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hamden : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Hamden : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Hartford :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
New Haven : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
New Haven :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
District of Columbia
Washington : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Washington : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Florida
Gainesville : University of Florida
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Gainesville : University of Florida
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Jacksonville : University of Florida, Jacksonville
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Jacksonville : East Coast Institute for Research
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Jacksonville : Borland-Groover Clinic
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Jacksonville : Borland-Groover Clinic
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Jacksonville : East Coast Institute for Research
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Jacksonville : University of Florida, Jacksonville
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Maitland : Center for Advanced Gastroenterology
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Maitland : Center for Advanced Gastroenterology
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Melbourne : Osler Clinical Research
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Melbourne : Osler Clinical Research
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Miami : University of Miami Miller School of Medicine
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Miami : University of Miami Miller School of Medicine
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
New Smyrna Beach : United Medical Research Institute
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
New Smyrna Beach : United Medical Research Institute
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Orlando : Internal Medicine Specialists
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Orlando : Compass Research LLC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Orlando : Internal Medicine Specialists
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Orlando : Compass Research LLC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Tampa : University of South Florida
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Tampa : West Wind'r Research & Development, LLC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Tampa : University of South Florida
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Tampa : West Wind'r Research & Development, LLC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Winter Park : Shafran Gastroenterology Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Winter Park : Shafran Gastroenterology Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Clearwater : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Clearwater : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Clearwater : Clinical Research of West Florida
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Clearwater : Clinical Research of West Florida
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Clearwater : Clinical Research of West Florida
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Crystal River : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Crystal River : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Deland : Avail Clinical Research, LLC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Gainesville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Gainesville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Gainesville : Drug Shipment Address
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Gainesville : Shands Endoscopy Center
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Gainesville : Shands Hospital at the University of Florida
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Gainesville : Florida Medical Research Institute
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Gainesville :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Gainsville : Shands Medical Plaza and Cancer Institute
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Inverness : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Inverness : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Jacksonville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Jacksonville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Jacksonville : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Jacksonville : Borland-Groover Clinic
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Jacksonville : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Kissimme : Gastroenterology Associates of Osceola
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Largo : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Lauderdale Lakes : Sunrise Medical Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Maitland : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Miami : Community Research Foundation, Inc
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Miami : Paramount Public Health & Research Management Services
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Miami : Jackson Memorial Hospital
Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease
Miami :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Miami : Research Site
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Miami : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Naples : Gastroenterology Group of Naples
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Naples : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Naples : Gastroenterology Group of Naples
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Naples : Gastroenterology Group of Naples
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
New Port Richey : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Orlando : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Orlando : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Port Orange : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Sanford : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Sanford : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Tampa : Clinical Research of West Florida, Inc.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Trinity : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Weston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Winter Park : Shafran Gastroenterology Center
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Winter Park : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Winter Park : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Winter Park : Shafran Gastroenterology Center
Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy
Winter Park : Shafran Gastroenterology Center
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Winter Park : Shafran Gastroenterology Center
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Winter Park : Shafran Gastroenterology Center
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Winter Park : Shafran Gasteroenterology Center
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Zephyrhills : Florida Medical Clinic, P.A.
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Georgia
Atlanta : Atlanta Gastroenterology Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Atlanta : Atlanta Gastroenterology Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Decatur : Atlanta Center for Gastroenterology, P.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Decatur : Atlanta Center for Gastroenterology, P.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Macon : Gastroenterology Associates of Central Georgia
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Macon : Gastroenterology Associates of Central Georgia
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Newnan : Digestive Research Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Newnan : Digestive Research Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Savannah : St. Joseph's/Candler Health System
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Savannah : St. Joseph's/Candler Health System
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Snellville : DLW Research System
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Snellville : DLW Research System
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Atlanta : Atlanta Gastroenterology Associates, LLC
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Atlanta : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Atlanta : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Atlanta : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Atlanta : Atlanta Gastroenterology Associates
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Atlanta : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Atlanta : Atlanta Gastroenterology Associates
Optimizing Cimzia in Crohn's Patients
Atlanta : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Atlanta : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Atlanta :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Decatur : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Decatur : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Decatur : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Decatur : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Macon : Gastroenterology Associates of Central Georgia
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Macon : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Macon : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Macon : Gastroenterology Associates of Central Georgia, LLC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Marietta : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Marietta : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Suwanee : Atlanta Gastroenterology Specialists, PC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Idaho
Boise : Selah Medical Center
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Boise :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Illinois
Chicago : Rush University Medical Center - Treatment Research Center
Dysbiosis in inflammatory bowel disease.
Chicago : University of Chicago Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Chicago : Rush University Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Chicago : University of Chicago Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Chicago : Rush University Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Urbana : Carle Clinic Association P.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Urbana : Carle Clinic Association P.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Arlington Heights : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Arlington Heights : Northwest Gastroenterologists
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Bolingbrook : Suburban Clinical Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Burr Ridge : Suburban Clinical Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Chicago : University of Chicago Hospital Medical Center
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Chicago : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Chicago : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Chicago : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Chicago : University of Chicago Medical Center
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Chicago : University of Chicago
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Chicago : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Chicago : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Chicago :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Evanston : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Evanston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Glenview : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Indiana
Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Anderson : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Evansville : Medisphere Medical Research Center, LLC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Indianapolis : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Indianapolis : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Indianapolis : IU School of Medicine - Gastroenterology
PillCam® Platform With the PillCam Crohn's Disease Capsule
Iowa
Clive : Digestive & Liver Consultants
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Clive : Iowa Digestive Disease Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Clive : Iowa Digestive Disease Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Clive : Digestive & Liver Consultants
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Clive : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Clive : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Clive : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Kansas
Kansas City : University Of Kansas
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Kansas City : University Of Kansas
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Topeka : Cotton O'Neil Digestive Health Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Topeka : Cotton O'Neil Digestive Health Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Pratt : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Topeka : Cotton O'Neil Digestive Healthcare
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Topeka : Cotton-O'Neil Clinical Research Center
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Topeka : Cotton-O'Neil Clinical Research Center
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Kentucky
Lexington : University of Kentucky Chandler Medical Center
Crohn’s Disease Research Study
Lexington : University of Kentucky Chandler Medical Center
Does your Crohn's require surgery?
Lexington : University of Kentucky Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Lexington : University of Kentucky Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Louisville : University Of Louisville
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Louisville : University Of Louisville
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Louisville : University Of Louisville
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Crestview Hills : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Lexington : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Lexington : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lexington : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Lexington : University of Kentucky
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Lexington : University of Kentucky Chandler Medical Center
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Lexington : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Lexington : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Louisville : University of Louisville School of Medicine
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Louisville : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Louisville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Louisiana
Baton Rouge : Gastroenterology Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Baton Rouge : Gastroenterology Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Baton Rouge : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Baton Rouge : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hammond : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hammond : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Hammond : Gastroenterology Research Of New Orleans
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Hammond : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Monroe : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Monroe : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Monroe : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
New Orleans : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
New Orleans : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
New Orleans :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Maine
Portland :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Maryland
Chevy Chase : Metropolitan Gastroenterology Group, P.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Chevy Chase : Metropolitan Gastroenterology Group, P.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Chevy Chase : Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
Ulcerative Colitis and Crohn’s Disease (IBD) Research Study
Prince Frederick : Shah Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Prince Frederick : Shah Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Annapolis : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Annapolis : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Baltimore : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Baltimore : University of Maryland, Baltimore
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Baltimore : University of Maryland, Baltimore
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Baltimore : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Chevy Chase : Metropolitan Gastroenterology Group. PC
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Chevy Chase : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Chevy Chase : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Chevy Chase : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Chevy Chase : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Chevy Chase : Chevy Chase Clinical Research
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Chevy Chase : Chevy Chase Clinical Research
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Chevy Chase : Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Chevy Chase : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Chevy Chase : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Towson : Endoscopic Microsurgery Associates PA
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Towson : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Towson : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Towson : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Massachusetts
Boston : Massachusetts General Hospital
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Boston : Boston Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Boston : Boston Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Boston : Massachusetts General Hospital
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Boston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Boston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Boston : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Boston : Tufts Medical Center
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Boston : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Boston : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Boston : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Boston :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Brockton : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Fall River : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Newton : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Worcester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Worcester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Worcester :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Michigan
Dearborn : The Center for Clinical Studies
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Dearborn : The Center for Clinical Studies
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Troy : Center for Digestive Health
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Troy : Center for Digestive Health
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Ann Arbor : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Ann Arbor : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Ann Arbor : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Ann Arbor : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Ann Arbor : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Chesterfield : Clinical Research Institute of Michigan
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Chesterfield : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Chesterfield : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Chesterfield : Clinical Research Institute of Michigan, LLC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Chesterfield : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Chesterfield : Clinical Research Institute of Michigan, LLC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Chesterfield : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Chesterfield : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Detroit :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Grand Rapids : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Kalamazoo : Beyer Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Novi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Novi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Troy : Center for Digestive Health
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Troy : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Troy : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Troy : Center for Digestive Health
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Troy : Surgical Centers of Michigan
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Troy : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Troy : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Troy : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Troy : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Troy : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Utica : Utica Surgery Center
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Wyoming : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Ypsilanti : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Ypsilanti : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Minnesota
Plymouth : Minnesota Gastroenterology, P.A.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Plymouth : Minnesota Gastroenterology, P.A.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Rochester : Mayo Clinic
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Rochester : Mayo Clinic
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Minneapolis :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Rochester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Rochester : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Rochester : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Rochester :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Rochester : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Saint Paul :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
St. Paul : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
St. Paul : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Mississippi
Tupelo : Digestive Health Specialists
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Tupelo : Digestive Health Specialists
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Ocean Springs : Digestive Health Center
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Ocean Springs : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Ocean Springs : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Missouri
Kansas City : Truman Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Kansas City : Truman Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Mexico : Center for Digestive and Liver Diseases, Inc.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Mexico : Center for Digestive and Liver Diseases, Inc.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
St. Louis : St. Louis Center for Clinical Research
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
St. Louis : Washington University
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
St. Louis : Washington University
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
St. Louis : St. Louis Center for Clinical Research
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Columbia : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Columbia : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Kansas City : The Children's Mercy Hospital
Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease
Lees Summit : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lees Summit : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Lee's Summit : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Lee's Summit : Midwest Center for Clinical Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Lee'S Summit : Midwest Center For Clinical Research
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Mexico : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Mexico : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Mexico : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Mexico : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Mexico : Center for Digestive and Liver Disease
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Mexico : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Saint Louis : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
St Louis : St Louis Center for Clinical Studies
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
St. Louis : St. Louis Center for Clinical Research
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
St. Louis : Saint Louis Center for Clinical Research
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
St. Louis : St. Louis Center for Clinical Studies
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Montana
Billings : Billings Clinic Research Center
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Nebraska
Boys Town :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Omaha : Quality Clinical Research, Inc.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Nevada
Las Vegas : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Las Vegas : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sparks : Reno Clinical Trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Lebanon : Dartmouth-Hitchcock Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Lebanon : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lebanon : Dartmouth Hitchcock Medical Center
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Lebanon : Dartmouth HItchcock Medical Center
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Manchester :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
New Jersey
Morristown : Affiliates in Gastroenterology PA
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Morristown : Affiliates in Gastroenterology PA
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Vineland : The Gastroenterology Group of South Jersey
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Vineland : The Gastroenterology Group of South Jersey
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Berlin : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Blackwood : South Jersey Medical Associates, P.A.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Egg Harbor : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Egg Harbor : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Egg Harbor Township : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Marlton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Marlton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Mays Landing : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Mays Landing : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Mays Landing :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Morristown : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Morristown :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Teaneck : Holy Name Medical Center
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
New York
Bayside : Hepatobiliary Associates of New York
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Bayside : Hepatobiliary Associates of New York
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Cheektowaga : Digestive Health Physician
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Cheektowaga : Digestive Health Physician
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Great Neck : Long Island Clinical Research Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Great Neck : Long Island Clinical Research Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Merrick : Long Island Gastroenterology Group, P.C.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Merrick : Long Island Gastroenterology Group, P.C.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
New York : Present Chapman Marion Steinlauf MD PC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
New York : New York Presbyterian Hospital
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
New York : Present Chapman Marion Steinlauf MD PC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
New York : New York Presbyterian Hospital
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Pittsford : Kim, Chung MD (Private Practice)
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Pittsford : Kim, Chung MD (Private Practice)
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Rochester : University of Rochester
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Rochester : University of Rochester
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Setauket : Long Island Digestive Disease Consultants
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Setauket : Long Island Digestive Disease Consultants
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Stonybrook : SUNY Stony Brook University Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Stonybrook : SUNY Stony Brook University Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Syracuse : Syracuse Gastroenterological Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Syracuse : Syracuse Gastroenterological Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Albany : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Albany : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Brooklyn : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Brooklyn : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Brooklyn :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Brooklyn : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Buffalo :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Cheektowaga : Digestive Health Physicians
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Great Neck : Long Island Clinical Research Associates, LLP
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Great Neck : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Great Neck : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Great Neck : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Great Neck : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Great Neck : Long Island Clinical Research Associates, LLP
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Great Neck : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Great Neck : Long Island Clinical Research Assoc., Llp
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Great Neck : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Great Neck : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Lake Success : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Lake Success : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Mineola :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
New Hyde Park :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
New York : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
New York : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
New York : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
New York : Pfizer Investigational Site
B0151003 Open-Label Extension Study
New York : Metropolitan Research Associates
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
New York : Mount Sinai School of Medicine
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
New York : Weill Cornell Medical College
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
New York : Mount Sinai School of Medicine
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
New York : Weill Cornell Medical College
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
New York :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
New York : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
New York : Mount Sinai School of Medicine
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
Poughkeepsie : Premier Medical Group of the Hudson Valley, PC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Poughkeepsie : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Poughkeepsie : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Rochester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Stony Brook : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Stony Brook :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Syracuse :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
North Carolina
Asheville : Asheville Gastroenterology Associates, P.A.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Asheville : Asheville Gastroenterology Associates, P.A.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Chapel Hill : University of North Carolina at Chapel Hill
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Chapel Hill : University of North Carolina at Chapel Hill
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Charlotte : Piedmont Medical Research
Crohn's Disease Study
Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Elkin : Northwest Piedmont Clinical Research, Inc.
An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Elkin : Northwest Piedmont Clinical Research, Inc.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Elkin : Northwest Piedmont Clinical Research, Inc.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Morganton : Burke Research Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Morganton : Burke Research Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Raleigh : Wake Research Associates
Crohn’s Disease Research Study
Raleigh : Wake Research Associates
Do you suffer from Crohn’s Disease?
Raleigh : Wake Research Associates
Study of Crohn's Disease Now Enrolling
Raleigh : Wake Research Associates
Treating your Crohn's disease doesn't have to be a solo act.
Winston Salem : Wake Forest University Baptist Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Winston Salem : Wake Forest University Baptist Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Chapel Hill : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Chapel Hill : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Chapel Hill : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Chapel Hill : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Chapel Hill :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Chapel Hill : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Charlotte : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Charlotte : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Charlotte : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Durham : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Durham : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Durham : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Durham :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Raleigh : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Raleigh : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Raleigh : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Raleigh : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Raleigh : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Winston-Salem : Clinical Trials of America, Inc.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Ohio
Beachwood : Gastroenterology Associates of Cleveland, Inc.
Research trial now enrolling for Humira ® for Crohn's Disease
Cincinnati : Consultants for Clinical Research Inc.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Cincinnati : Consultants for Clinical Research Inc.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Cleveland : Cleveland Clinic Foundation
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Cleveland : Cleveland Clinic Foundation
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Dayton : Dayton Science Institute
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Dayton : Dayton Science Institute
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Beavercreek : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Beavercreek : Dayton Gastroenterology
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Cincinnati : Consultants for Clinical Research
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Cincinnati : Ohio Gastroenterology and Liver
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Cincinnati : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Cincinnati : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Cincinnati : Consultants for Clinical Research, Inc
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Cincinnati : Consultants For Clinical Research
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Cleveland : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Columbus : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Columbus : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Dayton : Dayton Gastroenterology, Inc.
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Mentor : Great Lakes Gastroenterology
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Mentor : The Endoscopy Center of Lake County
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Mentor : Great Lakes Gastroenterology
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Oklahoma
Tulsa : Options Health Research
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Tulsa : Options Health Research
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Norman : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Oklahoma City : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Oklahoma City : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Oklahoma City : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Oklahoma City : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Oklahoma City :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Oklahoma City, : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Tulsa : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Tulsa : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Tulsa : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Tulsa : Gastroenterology United of Tulsa
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Tulsa : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Tulsa : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Oregon
Eugene : Clinical Trials of America, Inc
Are you a man or woman over 18, with moderate to severe, active Crohn’s Disease?
Portland : The Oregon Clinic-West Hills Gastroenterology
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Portland : The Oregon Clinic-West Hills Gastroenterology
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Bend : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Bend : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Portland : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Portland : Northwest Gastroenterology Clinic, LLD
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Portland : Oregon Health & Science University
Infliximab, Regulatory T Cells, IL2 and Crohn's Disease
Portland : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Springfield : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Pennsylvania
Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Danville :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Hershey : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Indiana : Shirish A. Amin, MD, PC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
King of Prussia : Omnicare Clinical Research, Inc.
Phase II Study of HMPL-004 in Subjects With Crohn's Disease
Philadelphia : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Philadelphia : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Philadelphia :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Pittsburg : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Pittsburg : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Pittsburgh : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Pittsburgh : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Pittsburgh : Children's Hospital of Pittsburgh of UPMC
Autologous Stem Cell Transplantation for Crohn's Disease
Pittsburgh : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Pittsburgh : University of Pittsburgh
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Sayre : Donald Guthrie Foundation for Education & Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Uniontown : Cherry Tree Medical
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Rhode Island
East Providence : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Warwick : Omega Medical Research
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
South Carolina
Charleston : Medical University Of SC CAR
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Charleston : Medical University Of SC CAR
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Columbia : Consultants in Gastroenterology
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Columbia : Consultants in Gastroenterology
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Greenville :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
North Charleston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
North Charleston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Tennessee
Germantown : Gastroenterology Center of the MidSouth, PC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Germantown : Gastroenterology Center of the MidSouth, PC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Nashville : Vanderbilt University Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Nashville : Vanderbilt University Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Knoxville :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Memphis :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Nashville : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Nashville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Nashville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Nashville : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Nashville : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Nashville : Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University
Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use
Nashville : Vanderbilt University Medical Center
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Nashville : Vanderbilt University Medical Center
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Nashville : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Nashville : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Nashville : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Texas
Austin : Austin Gastroenterology, PA
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Austin : Austin Gastroenterology, PA
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Houston : Jacon Medical Research Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Houston : Gastroenterology Consultants
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Houston : Bayou City Research, Ltd.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Houston : Jacon Medical Research Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Houston : Bayou City Research, Ltd.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Houston : Gastroenterology Consultants
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Pasadena : Digestive Health Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Pasadena : Digestive Health Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
San Antonio : Gastroenterology Clinic of San Antonio
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
San Antonio : Stone Oak Research Foundation
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
San Antonio : Stone Oak Research Foundation
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
San Antonio : Gastroenterology Clinic of San Antonio
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Tyler : Digestive Health Specialists of Tyler
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Tyler : Digestive Health Specialists of Tyler
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Austin : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Austin : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Austin : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Austin : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Austin : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Austin : Austin Gastroenterology PA/Professional Quality Research, Inc
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Austin : Austin Gastroenterology PA/Professional Quality Research, Inc.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Austin : Lovelace Scientific Resources, Inc.
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Dallas : Dallas VA Medical Center
Exacerbating Factors in Inflammatory Bowel Disease
Dallas :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Fort Worth :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Grapevine : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Grapevine : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Houston : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Houston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Houston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Houston : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Pasadena : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Pasadena : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
San Antonio : Gastroenterology Research Of San Antonio
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Sugar Land : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Tyler : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Tyler : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Tyler : Digestive Health Specialists of Tyler
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Tyler : Endoscopy Center of Tyler
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Utah
Sandy : Granite Peaks Gastroenterology
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Sandy : Granite Peaks Gastroenterology
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Ogden : Advanced Research Institute
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Ogden : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Ogden : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Ogden : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Salt Lake City : University of Utah
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Salt Lake City : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Salt Lake City : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Salt Lake City : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Salt Lake City : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Vermont
Burlington :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Virginia
Charlottesville : University of Virginia Health System
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Charlottesville : University of Virginia Health System
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Fairfax : Gastroenterology Associates of Northern Virginia
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Fairfax : Gastroenterology Associates of Northern Virginia
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Norfolk : Digestive and Liver Disease Specialist Ltd.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Norfolk : Digestive and Liver Disease Specialist Ltd.
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Richmond : Hunter Holmes McGuire VA Medical Center
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Richmond : Hunter Holmes McGuire VA Medical Center
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Charlottesville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Charlottesville :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Chesapeake : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Chesapeake : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Christiansburg : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Christiansburg : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Christiansburg : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Danville : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Danville : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Danville : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Fairfax : Gastroenterology Associates of Northern Virginia
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Fairfax :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Norfolk : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Norfolk : Cardiology Consultants
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Norfolk : Sentara Leigh Hospital
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Norfolk : Digestive and Liver Disease Specialists
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Norfolk : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Norfolk :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Richmond : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Richmond : McGuire Research Institute
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Richmond : McGuire Research Institute
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Richmond : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Virginia Beach : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Virginia Beach : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Washington
Bellevue : Northwest Gastroenterology Associates
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Bellevue : Northwest Gastroenterology Associates
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Edmonds : Puget Sound Medical Research
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Edmonds : Puget Sound Medical Research
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Seattle : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Seattle : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Seattle : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Seattle : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Seattle : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Seattle : University of Washington Medical Center
Induction of Clinical Response Using Rifaximin in Crohn's Disease
Seattle : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Seattle :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Seattle : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Wenatchee : Wenatchee Valley Medical Center
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
West Virginia
Morgantown : United BioSource Corporation
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Wisconsin
Madison : Pharmaseek, LLC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Madison : Pharmaseek, LLC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Milwaukee : Wisconsin Center for Advanced Research
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Milwaukee : Medical College Of Wisconsin
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Milwaukee : Wisconsin Center for Advanced Research
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Milwaukee : Medical College Of Wisconsin
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
View More »
Madison : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Madison : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Madison : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Madison : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Madison :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Milwaukee : The Center for Digestive Health
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Milwaukee : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Milwaukee : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Milwaukee : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Milwaukee :
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease
Wauwatosa : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Wauwatosa : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Australia
Adelaide : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Adelaide : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Adelaide : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Adelaide : Royal Adelaide Hospital
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Adelaide : Royal Adelaide Hospital
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
View More »
Adelaide : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Adelaide : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Adelaide : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Adelaide : Research Site
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Bankstown : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bankstown : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Bankstown : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Bedford Park : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Box Hill : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Brisbane : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Brisbane : QPharm
Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease
Cairns : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Cairns : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Central Queensland M C : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Central Queensland M C : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Concord : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Concord : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Fitzroy : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Fitzroy : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Fitzroy : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Fremantle : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Fremantle : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Fremantle : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Fremantle : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Fremantle : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Garran : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Garran : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hersten : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hersten : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Hersten : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Herston : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Herston : Research Site
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Kingswood : Nepean Hospital
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Kurralta Park : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Liverpool : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Liverpool : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Malvern : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Malvern : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Melbourne : Royal Melbourne Hospital
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Melbourne : Royal Melbourne Hospital
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Melbourne : Center for Clinical Studies
Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease
Parkville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Parkville : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Parkville : The Royal Melbourne Hospital
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Prahran : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Prahran : Research Site
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Prahran : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Prahran : Research Site
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Austria
Innsbruck : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Oberpullendorf : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Oberpullendorf : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Oberpullendorf : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
St Poelten : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
View More »
St. Veit/Glan : Krankenhaus
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Vienna : Site Reference ID/Investigator# 38145
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Wien : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Wien : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Wien : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Wien : Medizinische Universität
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Wien : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Wien : Pfizer Investigational Site
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs
Wien : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Belgium
Antwerp : UZ Antwerpen
Switching From Adalimumab to Infliximab
Belgium : Belgium
A Study of TRK-170 for the Treatment of Crohn's Disease
Bonheiden : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bonheiden : Site Reference ID/Investigator# 38147
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Bonheiden : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
View More »
Bonheiden : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Brussel : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Brussel : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Brussel : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Brussels : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Brussels : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Brussels : Pfizer Investigational Site
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs
Brussels : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Brussels : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Edegem : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Edegem : Site Reference ID/Investigator# 43966
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Genk : Hospital Oost-Limburg
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Gent : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Gent : Gent University Hospital
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Gent : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Gent : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Ghent : University Hospital Ghent
Switching From Adalimumab to Infliximab
Hasselt : Virga Jesse hospital
Switching From Adalimumab to Infliximab
Kortrijk : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Kortrijk : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Kortrijk : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Kortrijk : AZ Groeninge
Switching From Adalimumab to Infliximab
Leuven : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Leuven : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Leuven : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Leuven : Leuven University Hospital
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Leuven : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Leuven : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Leuven : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Leuven : UZ Leuven
Switching From Adalimumab to Infliximab
Liege : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Liege : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Liege : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Mouscron : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Mouscron : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Oostende : AZ Damiaan
Switching From Adalimumab to Infliximab
Ottignies : Clinique Saint-Pierre
Switching From Adalimumab to Infliximab
Roeselare : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Roeselare : Hospital Hartziekenhuis
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Roeselare : Site Reference ID/Investigator# 38146
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Roeselare : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Roeselare : Heilig Hartziekenhuis Roeselare
Switching From Adalimumab to Infliximab
Brazil
Curitiba : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Curitiba : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Goiás : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Ilha do Fundao - Rio de Janeiro : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Porto Alegre : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
View More »
Porto Alegre : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Porto Alegre : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Rio De Janeiro : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Rio De Janeiro : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Bulgaria
Bulgaria : Bulgaria
A Study of TRK-170 for the Treatment of Crohn's Disease
Pleven : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Rousse : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sofia : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Varna : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Canada
Brandon : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Brandon : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Calgary : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Calgary : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Calgary : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Calgary : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Calgary : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Calgary : Site Reference ID/Investigator# 38156
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Calgary : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Calgary : Division of Gastroenterology
Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)
Calgary : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Edmonton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Edmonton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Edmonton : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Edmonton : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Edmonton : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Halifax : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Halifax : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Halifax : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Halifax : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Halifax : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Hamilton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Hamilton : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hamilton : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Kingston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Kingston : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Kingston : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Kingston : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
London : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
London : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
London : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
London : Pfizer Investigational Site
B0151003 Open-Label Extension Study
London : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
London : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Montreal : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Montreal : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Montreal : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Montreal : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Montreal : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Montreal : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Montreal : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Montreal : Innovaderm Research Inc.
Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab
Ottawa : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Ottawa : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Ottawa : Investigational Site 5
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
Quebec : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Quebec : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Quebec : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Toronto : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Toronto : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Toronto : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Toronto : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Toronto : Investigational Site 4
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
Toronto : Investigational Site 1
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
Vancouver : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Vancouver : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Vancouver : Site Reference ID/Investigator# 45502
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Vancouver : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Vancouver : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Vancouver : Investigational Site 3
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
Vaughan : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Vaughan : Site Reference ID/Investigator# 38155
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Vaughan : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Victoria : Office of Dr. David C. Pearson
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Victoria : PerCuro Clinical Research Limited
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Victoria : Office of Drs. Ranjith Andrew Singh and Jamie D. Papp
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Winnipeg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Winnipeg : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Winnipeg : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Croatia
Avenija Gojka Suska 6 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Osijek : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Rijeka : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Zagreb : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Czech Republic
Brno : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Czech Republic : Czech Republic
A Study of TRK-170 for the Treatment of Crohn's Disease
Hradec Kralove : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Hradec Králové : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hradec Králové : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
View More »
Hradec Králové : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Hradec Kralove 12 : Site Reference ID/Investigator# 38159
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Olomouc : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Olomouc : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Olomouc : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Ostrava - Vitkovice : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Ostrava - Vitkovice : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Prague 7 : Site Reference ID/Investigator# 38158
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Praha 10 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Praha 10 : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Praha 4 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Praha 4 : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Praha 4 : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Praha 7 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Praha 7 : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Praha 7 : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Praha 9 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Praha 9 : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Usti Nad Labem : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Denmark
Aalborg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Aalborg : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Aalborg : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Aalborg : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Aarhus : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
View More »
Aarhus : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Aarhus : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Aarhus : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Aarhus C : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Aarhus C : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Herlev : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Herlev : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Herlev : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Herlev : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Herlev : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Hilleroed : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Hilleroed : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Hvidovre : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Hvidovre : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hvidovre : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Hvidovre : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Hvidovre : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Koebenhavn : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Koebenhavn NV : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Koebenhavn NV : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Odense : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Odense : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Odense : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Silkeborg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Estonia
Tallinn : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Tallinn : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Tartu : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Tartu : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
France
Amiens : Site Reference ID/Investigator# 38164
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Amiens Cedex 1 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Amiens Cedex 1 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Amiens cedex 1 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Amiens Cedex 1 : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
View More »
Bordeaux : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Caen Cedex 9 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Clichy : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Clichy cedex : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Clichy cedex : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
France : France
A Study of TRK-170 for the Treatment of Crohn's Disease
Lille : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lille Cedex : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Lille cedex : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Lille Cedex : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Lille Cedex : Site Reference ID/Investigator# 38163
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Lille cedex : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Marseille : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Nantes Cedex 1 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Nantes cedex 1 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Nice : Site Reference ID/Investigator# 42839
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Nice cedex 3 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Nice cedex 3 : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Paris : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Paris : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Paris : Hôpital Necker Enfants Malades, Faculté de Médecine Necker, INSERM EMI0212
Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis
Paris cedex 10 : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Paris cedex 10 : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Paris cedex 10 : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Paris Cedex 12 : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Paris Cedex 12 : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Paris Cedex 18 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Pessac : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Pessac : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Pessac cedex : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Pessac Cedex : Site Reference ID/Investigator# 42818
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Pessac cedex : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Pessac cedex : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Reims : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Rouen : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Rouen : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Saint-Priest en Jarez : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Saint-Priest en Jarez : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Toulouse : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Vandoeuvre Les Nancy : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Vandoeuvre Les Nancy : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Vandoeuvre Les Nancy : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Vandoeuvre Les Nancy : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Germany
Berlin : Novartis Investigative Site
A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
Berlin : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Berlin : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Berlin : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Berlin : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
View More »
Berlin : Pfizer Investigational Site
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs
Berlin : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Berlin : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Berlin : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Bochum : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Bochum : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Braunschweig : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Braunschweig : Klinikum Braunscheweig
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Brinkum/Stuhr : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Erlangen : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Erlangen : Department of Medicine I, University of Erlangen-Nuremberg
Endomicroscopy in IBD Patients
Frankfurt Am Main : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Frankfurt Am Main : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Frankfurt am Main : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Frankfurt am Main : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Frankfurt/Main : Klinikum Frankfurt
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Freiburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Halle : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Halle : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hamburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Hamburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hamburg : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hamburg : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Hamburg : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Hannover : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Hannover : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hannover : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hannover : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Hannover : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Haßloch : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Heidelberg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Heidelberg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Jena : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Jena : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Kiel : Novartis Investigative Site
A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
Kiel : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Kiel : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Kiel : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Kiel : Universitaetsklinikum Schleswig-Holstein
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Kiel : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Kiel : Site Reference ID/Investigator# 38170
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Ludwigshafen : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Lÿneburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lÿneburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Magdeburg : Site Reference ID/Investigator# 38168
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Mannheim : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Mannheim : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Minden : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Minden : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Minden : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Minden : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Minden : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Minden : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Muenster : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Munchen : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Munchen : Research Site
Safety Study of Entocort for Children With Crohn's Disease
München : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
München : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Münster : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Nurnberg : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Nurnberg : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Regensburg : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Regensburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Regensburg : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Regensburg : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Regensburg : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Stade : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Ulm : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Ulm : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Ulm : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Ulm : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Ulm : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Greece
Athens : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Athens : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Hong Kong
Hong Kong : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Shatin, New Territories : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Hungary
Bekescsaba : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bekescsaba : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Bekescsaba : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Békéscsaba : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Budapest : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
View More »
Budapest : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Budapest : Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Budapest : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Budapest N/A : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Debrecen : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Debrecen : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Gyula : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hungary : Hungary
A Study of TRK-170 for the Treatment of Crohn's Disease
Miskolc : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Mosonmagyaróvár : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Pecs : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Szeged : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Szekesfehervar : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Szekesfehervar : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Szekszard : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Szekszard : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Szekszard : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Szekszard : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Szekszárd : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Szekszárd : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Szekszárd : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Iceland
Reykjavik : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Reykjavik : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Ireland
Dublin : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Dublin : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Dublin 4 : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Dublin 9 : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Dublin 9 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Israel
Ashkelon : Barzilai Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Haifa : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Haifa : Rambam Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Haifa : Bnai Zion Hospital
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Holon : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
View More »
Holon : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Israel : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Israel : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Jerusalem : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Jerusalem : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Jerusalem : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Jerusalem : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Jerusalem : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Jerusalem : Shaarei Tzedek Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Jerusalem : Hadassah Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Kfar Saba : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Kfar Saba : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Kfar Saba : Meir Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Petach Tikva : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Petach Tikva : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Petach Tikva : Pfizer Investigational Site
B0151003 Open-Label Extension Study
Petah Tikva : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Petah-Tikva : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Ramat Gan : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Rehovot : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Rehovot : Kaplan Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Tel Aviv : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Tel Aviv : Tel Aviv Sourasky Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Tel Hashomer : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Tel Hashomer : Sheba Medical Center
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Zerifin : Assaf Harofeh
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Italy
Firenze : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Firenze : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Messina : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Messina : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Milano : Instituto Clinico Humanitas IRCCS
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
View More »
Napoli : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Roma : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Roma : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Roma : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Roma : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Roma : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Rome : Site Reference ID/Investigator# 38176
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Rome : Site Reference ID/Investigator# 38178
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Rozzano : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Rozzano : Site Reference ID/Investigator# 38177
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Japan
Aichi : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Aichi : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Aichi : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Akita : Site Ref # / Investigator 81105
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Chiba : Toho University Sakura Medical Center
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
View More »
Chiba : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Chiba : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Chiba : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Chikushino : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Chikushino : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Chikushino : Fukuoka University Chikushi Hospital
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Chikushino : Site Ref # / Investigator 79700
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Fukuoka : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Fukuoka : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Fukuoka : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Fukuoka : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Fukuoka : Site Ref # / Investigator 79643
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Fukuoka : Site Ref # / Investigator 79644
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Gifu : Site Ref # / Investigator 79694
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Hamamatsu : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Hamamatsu : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hamamatsu : Site Ref # / Investigator 79466
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Hamamatsu : Site Ref # / Investigator 79645
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Hirosaki : Site Ref # / Investigator 79642
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Hiroshima : Site Ref # / Investigator 79477
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Hokkaido : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hokkaido : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Hyogo : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Hyogo : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Iwafune : Site Ref # / Investigator 79681
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kagoshima : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Kagoshima : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Kagoshima : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Kagoshima : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Kagoshima : Site Ref # / Investigator 79450
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kagoshima-Shi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Kagoshima-Shi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Kashiwa : Site Ref # / Investigator 79675
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kashiwa : Site Ref # / Investigator 79478
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kawagoe : Site Ref # / Investigator 79693
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Koriyama : Site Ref # / Investigator 79454
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kumamoto : Site Ref # / Investigator 79445
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kurashiki : Site Ref # / Investigator 79636
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Kurume : Research Site
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Kyoto : Site Ref # / Investigator 79475
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Minato : Site Ref # / Investigator 79456
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Miyagi : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Miyagi : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Miyagi : Site Ref # / Investigator 68736
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Morioka : Site Ref # / Investigator 79446
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Nagasaki : Site Ref # / Investigator 79656
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Nagoya : Site Ref # / Investigator 79654
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Nagoya : Site Ref # / Investigator 79653
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Neyagawa : Site Ref # / Investigator 79459
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Nishinomiya : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Nishinomiya : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Nishinomiya : Site Ref # / Investigator 79465
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Ohtsu : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Ohtsu : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Oita : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Oita : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Oita : Site Ref # / Investigator 79677
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Oita : Site Ref # / Investigator 79695
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Okayama : Site Ref # / Investigator 79479
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Osaka : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Osaka : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Osaka : Osaka City University Hospital
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Osaka : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Osaka : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Osaka : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Osaka : Site Ref # / Investigator 79448
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Osaka : Site Ref # / Investigator 79449
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Osaka : Site Ref # / Investigator 79464
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Osaka-City : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Osaka-City : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Osakasayama : Site Ref # / Investigator 79657
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Otsu : Site Ref # / Investigator 79673
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Saga : Site Ref # / Investigator 79674
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Saitama : Site Ref # / Investigator 79455
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Sakura : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Sakura : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sakura : Site Ref # / Investigator 79476
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Sakura-Shi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Sakura-Shi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sapporo : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Sapporo : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sendai : National Hospital Organization Sendai Medlical Center
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Shinjuku : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Shinjuku : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Shunan : Site Ref # / Investigator 79453
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Suita : Site Ref # / Investigator 79634
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Takamatsu : Site Ref # / Investigator 79451
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Tokyo : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Tokyo : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Tokyo : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Tokyo : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Tokyo : Site Ref # / Investigator 79641
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Tokyo : Site Ref # / Investigator 79699
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Toyohashi : Site Ref # / Investigator 81102
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Toyota : Site Ref # / Investigator 81100
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Yokkaichi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Yokkaichi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Yokkaichi : Site Ref # / Investigator 79458
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Yokkaichi-Shi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Yokkaichi-Shi : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Yokohama : Site Ref # / Investigator 79473
Special Investigation on Long-term Treatment in Patients With Crohn's Disease
Korea, Republic of
Daegu : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Daegu : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Daegu : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Gyeonggi-Do : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Gyeonggi-Do : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Pusan : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Seoul : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Seoul : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Seoul : Severance Hospital, Yonsei University Health System
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Seoul : ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Seoul : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Seoul : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Seoul : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Wonju : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Latvia
Latvia : Latvia
A Study of TRK-170 for the Treatment of Crohn's Disease
Netherlands
Alkmaar : Site Reference ID/Investigator# 38181
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Almere : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Amersfoort : Site Reference ID/Investigator# 38179
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Amsterdam : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Amsterdam : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Amsterdam : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Amsterdam : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Amsterdam : AMC
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Amsterdam : VUMC
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Amsterdam : Site Reference ID/Investigator# 43042
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Amsterdam : Pfizer Investigational Site
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs
Amsterdam : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Amsterdam : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Amsterdam Zuidoost : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Groningen : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Leiden : Site Reference ID/Investigator# 38180
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Maastricht : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Maastricht : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Rotterdam : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Rotterdam : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Rotterdam : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Rotterdam : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
The Netherlands : The Netherlands
A Study of TRK-170 for the Treatment of Crohn's Disease
Utrecht : UMCU
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
New Zealand
Christchurch : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Christchurch : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Christchurch : University of Otago
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Christchurch : University of Otago
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Dunedin : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Dunedin : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Grafton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hamilton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Hamilton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Hamilton : Waikato Hospital
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Hamilton : Waikato Hospital
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Hastings : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Lower Hutt : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Otahuhu : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Plenty : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Tauranga. : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Tauranga. : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Wellington : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Wellington : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Norway
Ålesund : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bergen : Department of Medicine, Haukeland University Hospital
Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease
Gjettum : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Norway : Norway
A Study of TRK-170 for the Treatment of Crohn's Disease
Rud : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
View More »
Tønsberg : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Tønsberg : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Tromsø : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Tromsø : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Poland
Bydgoszcz : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Bydgoszcz : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Bydgoszcz : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bydgoszcz : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Elblag : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Elblag : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Krakow : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Kraków : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Kraków : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Lodz : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Lodz : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Łódź : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Łódź : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Poland : Poland
A Study of TRK-170 for the Treatment of Crohn's Disease
Rzeszów : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Rzeszów : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Sopot : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Torun : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Warszawa : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Warszawa : Local Institution
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Warszawa : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Warszawa : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Wroclaw : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Wrocław : Research Site
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Wrocław : Research Site
Safety Study of Entocort for Children With Crohn's Disease
Puerto Rico
Ponce : Pharmaseek, LLC
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Ponce : Pharmaseek, LLC
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Romania
Bucuresti : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Romania : Romania
A Study of TRK-170 for the Treatment of Crohn's Disease
Russian Federation
Ekaterinburg : 013
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Ekaterinburg : 28
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Kazan : 016
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Kazan : 012
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Moscow : 007
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 008
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 009
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 011
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 014
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 005
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 24
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 25
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Moscow : 31
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Nizhniy Novgorod : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Novgorod : 23
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Novosibirsk : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Orenburg : 29
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Orenburg : 20
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Orenburg : 21
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Saint Petersburg : 006
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Saint Petersburg : 001
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Saint Petersburg : 003
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Saint Petersburg : 004
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Samara : 015
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Samara : 18
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Shakhty : 017
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
St. Petersburg : 19
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Taganrog : 010
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Tolyatti : 26
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Ufa : 27
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Ufa : 22
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Ulyanovsk : 30
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Yaroslavl : 002
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)
Serbia
Belgrade : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Beograd : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Nis : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Serbica : Serbia
A Study of TRK-170 for the Treatment of Crohn's Disease
Slovakia
Bratislava : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Bratislava : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Nitra : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Nitra : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Nitra : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
View More »
Nitra : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Nove Mesto nad Vahom : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Nove Mesto nad Vahom : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Nove Mesto nad Vahom : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Presov : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Presov : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Trnava : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
South Africa
Bellville : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bellville : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Cape Town : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Cape Town : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Cape Town : Kingsbury Hospital
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
View More »
Claremont : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Claremont : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Claremont : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Durban : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Durban : Parklands Medical Centre
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Observatory : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Observatory : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Overport : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Overport : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Overport : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Pretoria : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Spain
Barcelona : Hospital Clinic de Barcelona
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Barcelona : Hospital Clinic de Barcelona
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Cordoba : Hospital Universitario Reina Sofia
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Elche : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Huelva : Hospital Juan Ramon Jimenez
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
View More »
Madrid : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Madrid : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Madrid : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Madrid : Hospital La Princesa
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Madrid : Hospital Clinico San Carlos
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Madrid : Hospital Universitario La Paz
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Madrid : Hospital 12 de Octubre
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Madrid : Site Reference ID/Investigator# 38185
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Madrid : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Majadahonda : Pfizer Investigational Site
A Study To Monitor Long-Term Treatment With PF-00547659
Majadahonda : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Pontevedra : Hospital de Montecelo
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Sabadell : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sabadell : Pfizer Investigational Site
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.
Sabadell (Barcelona) : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Sabadell (Barcelona) : GSK Investigational Site
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
Santiago De Compostela : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Seville : Hospital Virgen del Rocio
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Valencia : Hospital Universitario La Fe
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Valencia : Hospital de Sagunto
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Sweden
Gothenburg : Site Reference ID/Investigator# 39065
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Lund : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Lund : Site Reference ID/Investigator# 39064
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Lund : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Lund : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
View More »
Orebro : Site Reference ID/Investigator# 39066
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Stockholm : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Stockholm : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Sweden : Sweden
A Study of TRK-170 for the Treatment of Crohn's Disease
Uppsala : Site Reference ID/Investigator# 39082
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Switzerland
Bern : Site Reference ID/Investigator# 38192
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Zuerich : Novartis Investigative Site
A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
Zurich :
A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease
Zurich : Site Reference ID/Investigator# 38191
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Ukraine
Ukraine : Ukraine
A Study of TRK-170 for the Treatment of Crohn's Disease
United Kingdom
Birmingham : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Birmingham : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Birmingham : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Brighton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Brighton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
View More »
Bristol : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Bristol : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Bristol : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Bristol : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Bristol : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Cambridge : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Cambridge : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Cardiff : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Edinburgh : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Edinburgh : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Edinburgh : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Exeter : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Glasgow : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Gloucester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Gloucester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Harrow : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Harrow : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Harrow : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Harrow : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Liverpool : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Liverpool : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
London : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
London : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
London : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Manchester : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Manchester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Manchester : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Manchester : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Newcastle upon Tyne : Pfizer Investigational Site
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Newcastle-upon-Tyne : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Newcastle-upon-Tyne : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Newcastle-upon-Tyne : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Norwich : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Norwich : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Nottinghamshirecc : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Nottinghamshirecc : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Oxford : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Oxford : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Oxford : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Oxford : Site Reference ID/Investigator# 38196
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Oxford : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Oxford : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Salford : GSK Investigational Site
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Salford : GSK Investigational Site
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Salford : GSK Investigational Site
Open-Label Extension Study of GSK1605786A
Shrewsbury : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Shropshire : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Southampton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Southampton : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Sy4 : Updated
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Worthing : Worthing Hospital
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
